Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Real-world Evidence of Inebilizumab in IgG4-RD (REDUCE)

19. november 2026 oppdatert av: Wen Zhang, Peking Union Medical College Hospital

Real-world Evidence of Inebilizumab in Decreasing Corticosteroid Use and Improving Clinical Efficacy in IgG4-RD

The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.

This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:

Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.

Studietype

Observasjonsmessig

Registrering (Antatt)

100

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

All IgG4-related disease patients treated with inebilizumab.

Beskrivelse

Inclusion Criteria:

  1. Aged ≥18 years old;
  2. Meet the 2019 ACR/EULAR classification criteria or the 2020 Japanese diagnostic criteria for IgG4-RD;
  3. Plan to receive treatment with inebilizumab;
  4. Signed informed consent form.

Exclusion Criteria:

  1. Pregnant or lactating female patients;
  2. Participation in other interventional studies within 30 days prior to screening, or exposure to investigational products within 5 half-lives before enrollment, or planned participation in other interventional studies during the trial period;
  3. Patients with contraindications to inebilizumab treatment;
  4. Any other conditions deemed inappropriate for enrollment by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og intervensjoner

Gruppe / Kohort
Patients with IgG4-RD treated with inebilizumab

Patients with IgG4-RD receiving inebilizumab in the real-world setting

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Relapse rate
Tidsramme: One year after inebilizumab treatment

Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index

One year after inebilizumab treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of subjects achieving flare-free and treatment-free complete remission
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity

Three Months, six months and twelve months after inebilizumab treatment
Proportion of subjects achieving flare-free and glucocorticoid-free complete remission
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity

Three Months, six months and twelve months after inebilizumab treatment
Remission rate after inebilizumab treatment
Tidsramme: Six months and twelve months after inebilizumab treatment

The investigator determined that there was no evidence of disease activity at the visit

Six months and twelve months after inebilizumab treatment
IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Measured by IgG4-RD Responder Index

Three Months, six months and twelve months after inebilizumab treatment
IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Measured by IgG4-RD Damage Index

Three Months, six months and twelve months after inebilizumab treatment
Changes in serum IgG4 levels from baseline after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Laboratory markers

Three Months, six months and twelve months after inebilizumab treatment
Changes in serum B-cell levels from baseline after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Laboratory markers

Three Months, six months and twelve months after inebilizumab treatment
Total amount of glucocorticoids during inebilizumab administration
Tidsramme: One year after inebilizumab treatment

Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period.

One year after inebilizumab treatment
Improvement in patients' quality of life during inebilizumab administration
Tidsramme: One year after inebilizumab treatment

Quality of life measured by the EQ-5D-5L questionnaire

One year after inebilizumab treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

8. november 2026

Først innsendt som oppfylte QC-kriteriene

19. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere